Clinical Trials

7.5-Year Follow-Up Affirms Nivolumab’s Superiority Over Ipilimumab in Advanced Melanoma

At a 7.5-year follow-up, nivolumab (Opdivo)-based treatment regimens continued to display superior overall survival (OS) rates, duration of response (DOR), and health-related quality of life (HRQOL) compared with ipilimumab (Yervoy) monotherapy, according to a long-term follow-up analysis of CheckMate 067 (NCT01844505) presented during the 2022 ASCO Annual Meeting.

Read More
MRV News
Melanoma News
Archive
Menu